缬沙坦联合复方血栓通胶囊治疗原发性高血压的临床疗效

Clinical efficacy of valsartan combined with Fufang Xueshuantong capsule for treatment of primary hypertension

目的探讨采用缬沙坦联合复方血栓通胶囊治疗原发性高血压的临床疗效。方法 84例原发性高血压患者随机分为对照组和观察组各42例,对照组单纯口服缬沙坦,观察组同时口服缬沙坦及复方血栓通胶囊。对比两组患者的临床疗效以及治疗前后SBP、DBP、左心室舒张末期内径(LVDd)、左心室舒张末期室间隔厚度(LVST)、左心室舒张末期后壁厚度(LVPWT),随访6个月,观察心脑血管事件发生情况。结果观察组总有效率高于对照组(分别为95.24%、76.19%;P<0.05);治疗后两组SBP、DBP、LVDd、LVST以及LVPWT均较前改善,且观察组以上指标均低于对照组(P<0.05);观察组心脑血管事件发生率低于对照组(分别为14.29%、2.38%;P<0.05)。结论缬沙坦联合复方血栓通胶囊治疗原发性高血压疗效确切,可在控制血压的同时改善左心室肥厚情况,降低心脑血管不良事件发生率。

Objective To investigate the clinical efficacy of valsartan combined with Fufang Xueshuantong capsule for the treatment of primary hypertension. Methods A total of 84 patients with primary hypertension were randomly divided into control group and observation group, with 42 cases in each group. The control group was orally administered valsartan alone, and the observation group was orally administered valsartan combined with Fufang Xueshuantong capsule. The clinical efficacy, SBP, DBP, left ventricular end-diastolic diameter（LVDd） , left ventricular end-diastolic ventricular septal thiekness（LVST） and left ventricular end-diastolic posterior wall thickness （LVPWT） before and after treatment were compared between the two group. The incidence of cardiovascular events was observed within 6-month followed-up. Results The total effective rate in the observation group was higher than that in the control group（95.24% vs. 76.19% ;P 〈 0.05 ）. After treatment, SBP, DBP, LVDd, LVST and LVPWT improved in both groups, and the indices above in the observation group were lower than those in the control group （ P 〈 0.05 ）. The incidence rate of cardiovascular events in the observation group was lower than that in the control group （ 14.29% vs. 2.38% ;P 〈 0.05 ）. Conclusion Valsartan combined with Fufang Xueshuantong capsule can obtain a definite efficacy for the treatment of primary hypertension, can control the blood pressure and improve the left ventrieular hypertrophy,and reduce the incidence rate of cardiovascular events.